Callan Family Office LLC bought a new position in BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,025 shares of the company's stock, valued at approximately $248,000.
A number of other large investors have also added to or reduced their stakes in ONC. Farther Finance Advisors LLC bought a new stake in shares of BeOne Medicines in the second quarter worth $39,000. Signaturefd LLC purchased a new position in BeOne Medicines in the second quarter worth about $49,000. Parallel Advisors LLC bought a new stake in shares of BeOne Medicines during the 2nd quarter valued at about $59,000. Avanza Fonder AB purchased a new stake in shares of BeOne Medicines during the 2nd quarter valued at about $199,000. Finally, Aaron Wealth Advisors LLC bought a new position in shares of BeOne Medicines in the 2nd quarter worth approximately $200,000. Institutional investors own 48.55% of the company's stock.
Insider Buying and Selling at BeOne Medicines
In other news, SVP Chan Henry Lee sold 10,671 shares of the firm's stock in a transaction that occurred on Wednesday, October 8th. The stock was sold at an average price of $350.40, for a total value of $3,739,118.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John Oyler sold 27,803 shares of the company's stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $325.71, for a total value of $9,055,715.13. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 163,484 shares of company stock valued at $51,324,146. Corporate insiders own 6.62% of the company's stock.
Analyst Upgrades and Downgrades
ONC has been the subject of several analyst reports. Zacks Research raised shares of BeOne Medicines from a "hold" rating to a "strong-buy" rating in a report on Thursday, September 18th. Barclays assumed coverage on shares of BeOne Medicines in a research report on Thursday, September 18th. They issued an "overweight" rating and a $385.00 price target for the company. Morgan Stanley raised their price objective on shares of BeOne Medicines from $313.00 to $330.00 and gave the company an "overweight" rating in a research report on Friday, June 27th. Royal Bank Of Canada upped their target price on shares of BeOne Medicines from $349.00 to $364.00 and gave the stock an "outperform" rating in a report on Thursday, August 7th. Finally, Wall Street Zen upgraded BeOne Medicines from a "buy" rating to a "strong-buy" rating in a research note on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $340.30.
View Our Latest Analysis on ONC
BeOne Medicines Trading Up 0.6%
Shares of ONC stock opened at $318.02 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.72 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $34.85 billion, a price-to-earnings ratio of -183.83 and a beta of 0.31. BeOne Medicines Ltd. - Sponsored ADR has a 12-month low of $170.99 and a 12-month high of $355.30. The stock's 50-day moving average price is $323.90 and its 200-day moving average price is $278.16.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $0.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.36. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. The firm had revenue of $1.32 billion for the quarter, compared to analysts' expectations of $1.24 billion. Equities research analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current fiscal year.
BeOne Medicines Profile
(
Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.